Track topics on Twitter Track topics that are important to you
CAESAREA, Israel, June 4, 2015 (GLOBE NEWSWIRE) -- Elbit Vision Systems Ltd. (OTCBB:EVSNF), a pioneer in the science of camera-based automatic vision inspection for textile fabrics and technical webs, announced today that it has received another large order from a major manufacturer in the Asian Home Textile market. This $0.6 million sale to a world leading Indian-based conglomerate consists of IQ-TEX4 Automatic Inspection systems in conjunction with Shade Variation Analyzers. This order, along with the previously announced $1 million order from a Chinese manufacturer, pushes the Asian Home Textile market to 35% of the current $4.5 million backlog that EVS expects to deliver during 2015.
Sam Cohen, CEO of EVS, commented, "This order is another successful step in furthering our strategy to penetrate the home textile manufacturers in Asia. It is also a very important order with a leading Indian conglomerate which provides a strong reference for winning additional home textile business in this huge market. These orders strengthen our confidence for solid performance in 2015."
About Elbit Vision Systems Ltd. (EVS): www.evs.co.il
EVS offers a broad portfolio of automatic State-of-the-Art Visual Inspection Systems for both in-line and off-line applications, and process monitoring systems used to improve product quality, safety, and increase production efficiency. EVS' systems are used by over 800 customers, many of which are leading global companies.
This press release and other releases are available on www.evs.co.il
Safe Harbor Statement
This press release contains forward-looking statements. Such statements are subject to certain risks and uncertainties, such as market acceptance of new products and our ability to execute production on orders, which could cause actual results to differ materially from those in the statements included in this press release. Although EVS believes that the expectations reflected in such forward-looking statements are based on reasonable assumptions, it can give no assurance that its expectations will be achieved. EVS disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date hereof, whether as a result of new information, future events or otherwise. EVS undertakes no obligation to update forward-looking statements to reflect subsequently occurring events or circumstances.
CONTACT: Company Contact Information: Yaron Menashe, CFO Tel: +972 4 6107609 email@example.com Investor Relations Contact: Ehud Helft, Kenny Green Tel: +1 646 201 9246 firstname.lastname@example.orgNEXT ARTICLE
Standard antiretroviral therapy (ART) consists of the combination of at least three antiretroviral (ARV) drugs to maximally suppress the HIV virus and stop the progression of HIV disease. Huge reductions have been seen in rates of death and suffering whe...